Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Clinical Kidney Journal · 02.11.2026 · 19 (11)
DOI: 10.1093/ckj/sfag364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 02.11.2026. Verfasst von Takahiro Imaizumi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Background and hypothesis Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents.
Methods
Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed.
Results
Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively].
Conclusion
In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Nephrology, Shinseikai Dai-ichi Hospital, Nagoya, Japan.
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
ORCID-Profile: Takahiro Imaizumi, Nobuhiro Nishibori, Masaki Okazaki, Koya Nagase, Yoshihisa Takada, Tomoko Handa, Shoichi Maruyama
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Imaizumi, T., Nishibori, N., Okazaki, M., Nagase, K., Asano, Y., Takada, Y., Handa, T., Ito, D., Hashizume, A., & Maruyama, S. (2026). Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients. Clinical Kidney Journal, 19(11). https://doi.org/10.1093/ckj/sfag364
Vancouver
Imaizumi T, Nishibori N, Okazaki M, Nagase K, Asano Y, Takada Y, et al. Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients. Clinical Kidney Journal. 2026;19(11). doi:10.1093/ckj/sfag364
BibTeX
@article{Imaizumi2026,
author = {Imaizumi, Takahiro and Nishibori, Nobuhiro and Okazaki, Masaki and Nagase, Koya and Asano, Yuko and Takada, Yoshihisa and Handa, Tomoko and Ito, Daisuke and Hashizume, Atsushi and Maruyama, Shoichi},
title = {Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {11},
doi = {10.1093/ckj/sfag364}
}
EUVIMED